CDI-988 Safety Study in Healthy Participants
← catalyst calendarSponsored by Cocrystal Pharma, Inc. (industry) · COCP — their whole pipeline →. With Cocrystal Pharma Australia Pty Ltd., Beyond Drug Development Pty Ltd., Resolutum Global Pty Ltd., Scientia Clinical Research Pty Ltd.
Phase
Phase 1
Status
Completed
Study type
Interventional
Design
Randomized · Quadruple · Treatment
Enrollment
94actual
Sites
1
Country
Australia
Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →
Source: ClinicalTrials.gov, retrieved 2026-08-19
Dates
each axis at the precision it was filed, with the registry's own basis| Date | Filed | Basis | What it is |
|---|---|---|---|
| Start | 2023-09-27 | actual | When the study began enrolling |
| Primary completion | 2025-05-23 | actual | The date the last participant is measured for the primary outcome — the readout window |
| Study completion | 2025-07-23 | actual | The whole study's end, after follow-up |
| First posted | 2023-08-04 | actual | When this record first appeared on the registry |
| Results posted | 2026-08-19 | actual | When the sponsor posted results to the registry |
| Record updated | 2026-08-19 | actual | The sponsor's own last edit to this record — every projection above is as current as this date |
What it studies
Condition
- Healthy Volunteers
Interventions
- Drug: CDI-988
- Drug: Placebo
Primary outcomes
what the primary-completion date above is the date OFAdverse Events
measured Up to 17 days
Laboratory Abnormalities
measured Up to 17 days
Vital Signs
measured Day 1 to 7 days after last dose
ECGs
measured Day 1 to 7 days after last dose
Posted documents
hosted by the registry — we link, never re-serveStudy Protocolposted 2025-04-03 · 1.7 MB · Prot_000.pdf
Statistical Analysis Planposted 2025-06-25 · 11.5 MB · SAP_001.pdf
Permalink · COCP's whole pipeline · Catalyst calendar · Every registered study · What changed